Safety Study of High-Dose Ranibizumab for Polypoidal Choroidal Vasculopathy
Status:
Unknown status
Trial end date:
2013-02-01
Target enrollment:
Participant gender:
Summary
Monthly, continuous anti-vegf therapy for patients presenting with active polypoidal
choroidal vasculopathy. Two arms, treatment naive and previously treated with an FDA approved
anti-VEGF therapy, will be randomized and dosed with open label 2.0mg ranibizumab.